nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Extravasation—Carboplatin—bone cancer	0.0729	0.0729	CcSEcCtD
Oritavancin—Bilirubin total increased—Epirubicin—bone cancer	0.0477	0.0477	CcSEcCtD
Oritavancin—Bilirubin total increased—Doxorubicin—bone cancer	0.0442	0.0442	CcSEcCtD
Oritavancin—Allergic cutaneous angiitis—Methotrexate—bone cancer	0.0322	0.0322	CcSEcCtD
Oritavancin—Abscess—Cisplatin—bone cancer	0.0236	0.0236	CcSEcCtD
Oritavancin—Infection—Carboplatin—bone cancer	0.0225	0.0225	CcSEcCtD
Oritavancin—Extravasation—Cisplatin—bone cancer	0.0214	0.0214	CcSEcCtD
Oritavancin—Leukocytoclastic vasculitis—Methotrexate—bone cancer	0.0209	0.0209	CcSEcCtD
Oritavancin—Cellulitis—Cisplatin—bone cancer	0.0205	0.0205	CcSEcCtD
Oritavancin—Hyperuricaemia—Cisplatin—bone cancer	0.0201	0.0201	CcSEcCtD
Oritavancin—Blood uric acid increased—Cisplatin—bone cancer	0.019	0.019	CcSEcCtD
Oritavancin—Wheezing—Cisplatin—bone cancer	0.0181	0.0181	CcSEcCtD
Oritavancin—Abscess—Methotrexate—bone cancer	0.0129	0.0129	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.0122	0.0122	CcSEcCtD
Oritavancin—Abscess—Epirubicin—bone cancer	0.0121	0.0121	CcSEcCtD
Oritavancin—Extravasation—Methotrexate—bone cancer	0.0117	0.0117	CcSEcCtD
Oritavancin—Abscess—Doxorubicin—bone cancer	0.0112	0.0112	CcSEcCtD
Oritavancin—Hyperuricaemia—Methotrexate—bone cancer	0.011	0.011	CcSEcCtD
Oritavancin—Extravasation—Epirubicin—bone cancer	0.011	0.011	CcSEcCtD
Oritavancin—Cellulitis—Epirubicin—bone cancer	0.0105	0.0105	CcSEcCtD
Oritavancin—Blood uric acid increased—Methotrexate—bone cancer	0.0104	0.0104	CcSEcCtD
Oritavancin—Hyperuricaemia—Epirubicin—bone cancer	0.0103	0.0103	CcSEcCtD
Oritavancin—Extravasation—Doxorubicin—bone cancer	0.0102	0.0102	CcSEcCtD
Oritavancin—Blood bilirubin increased—Epirubicin—bone cancer	0.0101	0.0101	CcSEcCtD
Oritavancin—Blood uric acid increased—Epirubicin—bone cancer	0.00976	0.00976	CcSEcCtD
Oritavancin—Cellulitis—Doxorubicin—bone cancer	0.00975	0.00975	CcSEcCtD
Oritavancin—Hyperuricaemia—Doxorubicin—bone cancer	0.00956	0.00956	CcSEcCtD
Oritavancin—Blood bilirubin increased—Doxorubicin—bone cancer	0.00937	0.00937	CcSEcCtD
Oritavancin—Connective tissue disorder—Cisplatin—bone cancer	0.00921	0.00921	CcSEcCtD
Oritavancin—Blood uric acid increased—Doxorubicin—bone cancer	0.00903	0.00903	CcSEcCtD
Oritavancin—Cardiac disorder—Cisplatin—bone cancer	0.00869	0.00869	CcSEcCtD
Oritavancin—Immune system disorder—Cisplatin—bone cancer	0.00846	0.00846	CcSEcCtD
Oritavancin—Mediastinal disorder—Cisplatin—bone cancer	0.00844	0.00844	CcSEcCtD
Oritavancin—Malnutrition—Cisplatin—bone cancer	0.00816	0.00816	CcSEcCtD
Oritavancin—Anaemia—Cisplatin—bone cancer	0.00754	0.00754	CcSEcCtD
Oritavancin—Hypoglycaemia—Epirubicin—bone cancer	0.00713	0.00713	CcSEcCtD
Oritavancin—Myalgia—Cisplatin—bone cancer	0.00694	0.00694	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.0069	0.0069	CcSEcCtD
Oritavancin—Infection—Cisplatin—bone cancer	0.00661	0.00661	CcSEcCtD
Oritavancin—Hypoglycaemia—Doxorubicin—bone cancer	0.00659	0.00659	CcSEcCtD
Oritavancin—Nervous system disorder—Cisplatin—bone cancer	0.00653	0.00653	CcSEcCtD
Oritavancin—Tachycardia—Cisplatin—bone cancer	0.0065	0.0065	CcSEcCtD
Oritavancin—Skin disorder—Cisplatin—bone cancer	0.00647	0.00647	CcSEcCtD
Oritavancin—Eosinophilia—Methotrexate—bone cancer	0.00636	0.00636	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.00626	0.00626	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Epirubicin—bone cancer	0.00613	0.00613	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00606	0.00606	CcSEcCtD
Oritavancin—Eosinophilia—Epirubicin—bone cancer	0.00595	0.00595	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00579	0.00579	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Cisplatin—bone cancer	0.00575	0.00575	CcSEcCtD
Oritavancin—Infestation—Methotrexate—bone cancer	0.00573	0.00573	CcSEcCtD
Oritavancin—Infestation NOS—Methotrexate—bone cancer	0.00573	0.00573	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00568	0.00568	CcSEcCtD
Oritavancin—Eosinophilia—Doxorubicin—bone cancer	0.00551	0.00551	CcSEcCtD
Oritavancin—Infestation—Epirubicin—bone cancer	0.00536	0.00536	CcSEcCtD
Oritavancin—Infestation NOS—Epirubicin—bone cancer	0.00536	0.00536	CcSEcCtD
Oritavancin—Infestation NOS—Doxorubicin—bone cancer	0.00496	0.00496	CcSEcCtD
Oritavancin—Infestation—Doxorubicin—bone cancer	0.00496	0.00496	CcSEcCtD
Oritavancin—Hypersensitivity—Cisplatin—bone cancer	0.0049	0.0049	CcSEcCtD
Oritavancin—Erythema multiforme—Methotrexate—bone cancer	0.00486	0.00486	CcSEcCtD
Oritavancin—Cardiac disorder—Methotrexate—bone cancer	0.00477	0.00477	CcSEcCtD
Oritavancin—Oedema peripheral—Epirubicin—bone cancer	0.00474	0.00474	CcSEcCtD
Oritavancin—Connective tissue disorder—Epirubicin—bone cancer	0.00473	0.00473	CcSEcCtD
Oritavancin—Immune system disorder—Methotrexate—bone cancer	0.00464	0.00464	CcSEcCtD
Oritavancin—Mediastinal disorder—Methotrexate—bone cancer	0.00463	0.00463	CcSEcCtD
Oritavancin—Diarrhoea—Cisplatin—bone cancer	0.00455	0.00455	CcSEcCtD
Oritavancin—Erythema multiforme—Epirubicin—bone cancer	0.00455	0.00455	CcSEcCtD
Oritavancin—Malnutrition—Methotrexate—bone cancer	0.00448	0.00448	CcSEcCtD
Oritavancin—Cardiac disorder—Epirubicin—bone cancer	0.00447	0.00447	CcSEcCtD
Oritavancin—Oedema peripheral—Doxorubicin—bone cancer	0.00439	0.00439	CcSEcCtD
Oritavancin—Connective tissue disorder—Doxorubicin—bone cancer	0.00437	0.00437	CcSEcCtD
Oritavancin—Immune system disorder—Epirubicin—bone cancer	0.00435	0.00435	CcSEcCtD
Oritavancin—Mediastinal disorder—Epirubicin—bone cancer	0.00434	0.00434	CcSEcCtD
Oritavancin—Vomiting—Cisplatin—bone cancer	0.00423	0.00423	CcSEcCtD
Oritavancin—Erythema multiforme—Doxorubicin—bone cancer	0.00421	0.00421	CcSEcCtD
Oritavancin—Rash—Cisplatin—bone cancer	0.0042	0.0042	CcSEcCtD
Oritavancin—Dermatitis—Cisplatin—bone cancer	0.00419	0.00419	CcSEcCtD
Oritavancin—Malnutrition—Epirubicin—bone cancer	0.00419	0.00419	CcSEcCtD
Oritavancin—Anaemia—Methotrexate—bone cancer	0.00414	0.00414	CcSEcCtD
Oritavancin—Cardiac disorder—Doxorubicin—bone cancer	0.00413	0.00413	CcSEcCtD
Oritavancin—Immune system disorder—Doxorubicin—bone cancer	0.00402	0.00402	CcSEcCtD
Oritavancin—Mediastinal disorder—Doxorubicin—bone cancer	0.00401	0.00401	CcSEcCtD
Oritavancin—Nausea—Cisplatin—bone cancer	0.00395	0.00395	CcSEcCtD
Oritavancin—Malnutrition—Doxorubicin—bone cancer	0.00388	0.00388	CcSEcCtD
Oritavancin—Anaemia—Epirubicin—bone cancer	0.00387	0.00387	CcSEcCtD
Oritavancin—Myalgia—Methotrexate—bone cancer	0.00381	0.00381	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00378	0.00378	CcSEcCtD
Oritavancin—Infection—Methotrexate—bone cancer	0.00363	0.00363	CcSEcCtD
Oritavancin—Nervous system disorder—Methotrexate—bone cancer	0.00358	0.00358	CcSEcCtD
Oritavancin—Anaemia—Doxorubicin—bone cancer	0.00358	0.00358	CcSEcCtD
Oritavancin—Myalgia—Epirubicin—bone cancer	0.00357	0.00357	CcSEcCtD
Oritavancin—Skin disorder—Methotrexate—bone cancer	0.00355	0.00355	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00354	0.00354	CcSEcCtD
Oritavancin—Infection—Epirubicin—bone cancer	0.0034	0.0034	CcSEcCtD
Oritavancin—Nervous system disorder—Epirubicin—bone cancer	0.00335	0.00335	CcSEcCtD
Oritavancin—Tachycardia—Epirubicin—bone cancer	0.00334	0.00334	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00333	0.00333	CcSEcCtD
Oritavancin—Skin disorder—Epirubicin—bone cancer	0.00332	0.00332	CcSEcCtD
Oritavancin—Myalgia—Doxorubicin—bone cancer	0.0033	0.0033	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00328	0.00328	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Methotrexate—bone cancer	0.00315	0.00315	CcSEcCtD
Oritavancin—Infection—Doxorubicin—bone cancer	0.00314	0.00314	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00311	0.00311	CcSEcCtD
Oritavancin—Nervous system disorder—Doxorubicin—bone cancer	0.0031	0.0031	CcSEcCtD
Oritavancin—Tachycardia—Doxorubicin—bone cancer	0.00309	0.00309	CcSEcCtD
Oritavancin—Skin disorder—Doxorubicin—bone cancer	0.00307	0.00307	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Epirubicin—bone cancer	0.00295	0.00295	CcSEcCtD
Oritavancin—Urticaria—Methotrexate—bone cancer	0.0029	0.0029	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00288	0.00288	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00273	0.00273	CcSEcCtD
Oritavancin—Urticaria—Epirubicin—bone cancer	0.00272	0.00272	CcSEcCtD
Oritavancin—Hypersensitivity—Methotrexate—bone cancer	0.00269	0.00269	CcSEcCtD
Oritavancin—Pruritus—Methotrexate—bone cancer	0.00258	0.00258	CcSEcCtD
Oritavancin—Hypersensitivity—Epirubicin—bone cancer	0.00252	0.00252	CcSEcCtD
Oritavancin—Urticaria—Doxorubicin—bone cancer	0.00251	0.00251	CcSEcCtD
Oritavancin—Diarrhoea—Methotrexate—bone cancer	0.0025	0.0025	CcSEcCtD
Oritavancin—Pruritus—Epirubicin—bone cancer	0.00242	0.00242	CcSEcCtD
Oritavancin—Dizziness—Methotrexate—bone cancer	0.00242	0.00242	CcSEcCtD
Oritavancin—Diarrhoea—Epirubicin—bone cancer	0.00234	0.00234	CcSEcCtD
Oritavancin—Hypersensitivity—Doxorubicin—bone cancer	0.00233	0.00233	CcSEcCtD
Oritavancin—Vomiting—Methotrexate—bone cancer	0.00232	0.00232	CcSEcCtD
Oritavancin—Rash—Methotrexate—bone cancer	0.0023	0.0023	CcSEcCtD
Oritavancin—Dermatitis—Methotrexate—bone cancer	0.0023	0.0023	CcSEcCtD
Oritavancin—Headache—Methotrexate—bone cancer	0.00229	0.00229	CcSEcCtD
Oritavancin—Dizziness—Epirubicin—bone cancer	0.00226	0.00226	CcSEcCtD
Oritavancin—Pruritus—Doxorubicin—bone cancer	0.00224	0.00224	CcSEcCtD
Oritavancin—Vomiting—Epirubicin—bone cancer	0.00217	0.00217	CcSEcCtD
Oritavancin—Nausea—Methotrexate—bone cancer	0.00217	0.00217	CcSEcCtD
Oritavancin—Diarrhoea—Doxorubicin—bone cancer	0.00216	0.00216	CcSEcCtD
Oritavancin—Rash—Epirubicin—bone cancer	0.00216	0.00216	CcSEcCtD
Oritavancin—Dermatitis—Epirubicin—bone cancer	0.00215	0.00215	CcSEcCtD
Oritavancin—Headache—Epirubicin—bone cancer	0.00214	0.00214	CcSEcCtD
Oritavancin—Dizziness—Doxorubicin—bone cancer	0.00209	0.00209	CcSEcCtD
Oritavancin—Nausea—Epirubicin—bone cancer	0.00203	0.00203	CcSEcCtD
Oritavancin—Vomiting—Doxorubicin—bone cancer	0.00201	0.00201	CcSEcCtD
Oritavancin—Rash—Doxorubicin—bone cancer	0.00199	0.00199	CcSEcCtD
Oritavancin—Dermatitis—Doxorubicin—bone cancer	0.00199	0.00199	CcSEcCtD
Oritavancin—Headache—Doxorubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Oritavancin—Nausea—Doxorubicin—bone cancer	0.00188	0.00188	CcSEcCtD
